ArticleOncotarget2017
Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis.Journal of ovarian research · 2022Pooled it
- Hormone replacement therapy after surgery for epithelial ovarian cancer.The Cochrane database of systematic reviews · 2020Pooled it
- Progress of estrogen receptor and splice variants in ovarian carcinoma.Journal of ovarian research · 2026Review
- Ecological and evolutionary dynamics to design and improve ovarian cancer treatment.Clinical and translational medicine · 2024Review
- CA-125:CA72-4 ratio - towards a promising cost-effective tool in ovarian cancer diagnosis and monitoring of post-menopausal women under hormone treatment.Journal of ovarian research · 2024Review
- Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.Journal of experimental & clinical cancer research : CR · 2024Review
- Clinico-Morphological Features and Immunohistochemical Profile of a Rare Case of Three Synchronous Primary Malignancies in the Female Genital Tract.Reports (MDPI) · 2024Article
- Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options.Biomedicines · 2023Review
- A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.Diagnostic pathology · 2023Article
- Article
- Decreased risk of ovarian cancer associated with rs9898876 sex hormone-binding globulin gene variant.Molecular biology reports · 2022Article
- Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers.International journal of molecular sciences · 2022Review
- Article
- Frontline Maintenance Treatment for Ovarian Cancer.Current oncology reports · 2021Review
- Impact of Preanalytical Factors on the Measurement of Tumor Tissue Biomarkers Using Immunohistochemistry.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Article
- Progesterone reduces cell survival in primary cultures of endometrioid ovarian cancer.Journal of ovarian research · 2019Article
- Linking obesity-induced leptin-signaling pathways to common endocrine-related cancers in women.Endocrine · 2019Review
- Sexual steroid hormone receptors profiles of ovarian carcinoma in Mexican women.Endocrine connections · 2018Article
- The Role of the Estrogen Pathway in the Tumor Microenvironment.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAccumulated studies have investigated the prognostic significance of estrogen receptor expression in epithelial ovarian cancer, but results remain controversial. The aim of this study was to perform a meta-analysis to clarify the prognostic value of estrogen receptor expression in epithelial ovarian cancer.
methodsA systematic search was performed in PUBMED, EMBASE, and COCHRANE databases to identify relevant studies up to December 2016. The pooled hazard rates (HR) with 95% confidence intervals (CIs) for overall survival and time to tumor progression were calculated and then weighted and pooled in this meta-analysis with a random-effect model.
resultsThirty-five studies with a total of 5824 patients were included. In brief, the expression of estrogen receptor was associated with an improved overall survival (HR = 0.86, 95% CI = 0.76-0.97), whereas there was no significant difference between estrogen receptor and time to tumor progression among epithelial ovarian cancer patients. Subgroup analysis revealed that estrogen receptor expression was significantly correlated with overall survival in different subgroups, such as in unclassified epithelial ovarian cancer (HR= 0.80, 95% CI = 0.66-0.95), studies using immunohistochemistry detection method (HR= 0.85, 95% CI = 0.73-1.00), European population (HR= 0.75, 95% CI = 0.60-0.94) and estrogen receptor α subtype (HR= 0.78, 95% CI = 0.62-0.98).
conclusionsEstrogen receptor, especially estrogen receptor α, was associated with an improved overall survival in epithelial ovarian cancer. Estrogen receptor expression may be a promising prognostic factor in epithelial ovarian cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.